CyGenica, a pioneering biotech startup, revolutionises intracellular therapeutics development through their drug delivery platform, GEENIE, which promises to redefine the landscape of pharmaceutical treatments. GEENIE is not just a platform; it's a molecular tool designed to make intracellular drug delivery effortless, efficient, & significantly more targeted. GEENIE enters the target cell with a fundamentally new approach, bypasses endosomes enhancing the therapeutic efficiency of drugs. We are currently undergoing our first commercial validation for SiRNA & ASO delivery with two esteemed pharma partners, with evaluation agreements already signed. We aim to build a robust pipeline through partnerships with four global leaders. These include a collaboration in SiRNA, addressing a Serviceable Addressable Market (SAM) of 12.6 billion USD; another in ASO, tapping into a 6 billion USD market; and a third in CRISPR, targeting a market size of 7 billion USD.